First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A.

Kingsley Hampton Pratima ChowdaryS DunkleyS EhrenforthL JacobsenA NeffE SantagostinoJ SatharH TakedaniC M TakemotoC Négrier

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2017)

The data showed that N8-GP was effective and well tolerated for the prevention and treatment of bleeds during major surgery; such FVIII products with extended half-lives may modify current treatment schedules, enabling fewer infusions and earlier patient discharge.

Keyphrases

minimally invasive
coronary artery bypass
early onset
case report
coronary artery disease
atrial fibrillation
big data
drug induced